Which has the lower trailing P/E, BLFS or LMAT?

LMAT has the lower trailing P/E: BLFS trades at 37.72 and LMAT at 27.95. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, BLFS or LMAT?

Over the past five years, LMAT grew revenue faster — BLFS at a 6.78% CAGR versus LMAT at 11.76%.

Does BLFS or LMAT pay a bigger dividend?

LMAT pays a dividend (1.17% yield), while BLFS has no payments in the available dividend history.

Is BLFS or LMAT more profitable?

BLFS runs the higher net margin — BLFS at 49.06% versus LMAT at 25.02%.

How have BLFS and LMAT total returns compared?

Over the past 10 years, BLFS delivered 36.27% and LMAT delivered 16.21% annualized total return. Past performance doesn't predict future results.

BioLife Solutions, Inc. (BLFS) vs LeMaitre Vascular, Inc. (LMAT)

A side-by-side comparison of BioLife Solutions, Inc. and LeMaitre Vascular, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

BLFS

BioLife Solutions, Inc.

$1.89B

$38.61HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

LMAT

LeMaitre Vascular, Inc.

$1.82B

$79.66HealthcareDelayed quote: Oct 6, 2026, 11:04 AM EDT

Total return — BLFS vs LMAT

growth of $100 · dividends reinvested · last 10y

BLFS +2119.0% (+36.3%/yr)LMAT +349.0% (+16.2%/yr)BLFS compounded faster over this window

BLFS LMAT

BLFS vs LMAT: by the numbers

•BLFS is the larger company ($1.89B vs $1.82B market cap).
•LMAT trades at the lower trailing earnings multiple (27.95 vs 37.72 P/E), one valuation lens rather than an overall verdict.
•BLFS converts more revenue to profit (49.06% vs 25.02% net margin).
•LMAT grew revenue faster over the past five years (11.76% vs 6.78% CAGR).
•LMAT pays a dividend (1.17% yield), while BLFS has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	BLFS	LMAT
P/E ratio	37.72	27.95
Forward P/E	64.35	27.73
PEG ratio	N/A	1.44
P/S ratio	18.35	6.94
P/B ratio	4.49	4.33
EV / EBITDA	170.26	21.83
FCF yield	N/A	4.06%

Profitability

Metric	BLFS	LMAT
Gross margin	64.48%	72.90%
Operating margin	-1.12%	29.46%
Net margin	49.06%	25.02%
ROE	12.01%	15.62%
ROIC	1.72%	9.81%

Dividends

Metric	BLFS	LMAT
Dividend yield	N/A	1.17%
Payout ratio	N/A	33.33%

Growth (annualized)

Metric	BLFS	LMAT
Revenue CAGR (5Y)	6.78%	11.76%
EPS CAGR (5Y)	N/A	19.42%
FCF CAGR (5Y)	N/A	13.06%
Total return CAGR (5Y)	-0.77%	9.79%

Frequently asked

Which has the lower trailing P/E, BLFS or LMAT?: LMAT has the lower trailing P/E: BLFS trades at 37.72 and LMAT at 27.95. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, BLFS or LMAT?: Over the past five years, LMAT grew revenue faster — BLFS at a 6.78% CAGR versus LMAT at 11.76%.
Does BLFS or LMAT pay a bigger dividend?: LMAT pays a dividend (1.17% yield), while BLFS has no payments in the available dividend history.
Is BLFS or LMAT more profitable?: BLFS runs the higher net margin — BLFS at 49.06% versus LMAT at 25.02%.
How have BLFS and LMAT total returns compared?: Over the past 10 years, BLFS delivered 36.27% and LMAT delivered 16.21% annualized total return. Past performance doesn't predict future results.

Go deeper

Full BLFS analysis Full LMAT analysis Interactive comparison tool

Dig into the metrics

BioLife Solutions P/E ratio LeMaitre Vascular P/E ratio LeMaitre Vascular dividend yield BioLife Solutions ROE LeMaitre Vascular ROE BioLife Solutions operating margin LeMaitre Vascular operating margin BioLife Solutions revenue growth LeMaitre Vascular revenue growth BioLife Solutions free cash flow LeMaitre Vascular free cash flow

BioLife Solutions & LeMaitre Vascular appear in these rankings

Highest FCF Yield Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.